Dr. Sharyle Fowler Publications

  • Hill JE, Pena-Sanchez JN, Fernando C, Freitas AC, Gamage NW, Fowler S.  Composition and stability of the vaginal microbiota of pregnant women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. Epub ahead of print (17 Dec 2021).
 
  • Kuenzig ME, Windsor JW, Barrett L, Bernstein CH, Bitton A, Carroll MW, Chauhan U, Coward S, Fowler S, Ghia J-E, Geist R, Gibson DL, Graff LA, Griffiths AM, Guoxian Huang J, Jones JL, Khanna R, Lakatos PL, Lee K, Mack DR, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Panaccione R, Seow CH, Singh J, Tandon P, Targownki LE, Zelinsky S, Benchiml EI, Kaplan GG.  Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. Journal of the Canadian Association of Gastroenterology, 2021, 4(S2):S1-9.
 
  • Kaplan GG, Windsor JW, Crain J, Barrett L, Bernstein CN, Bitton A, Chauhan U, Coward S, Fowler S, Ghia J-E, Gibson DL, Griffiths AM, Jones JL, Khanna R, Kuenzig ME, Lakatos PL, Lee K, Mack DR, Marshall JK, Mawani M, Murthy SK, Panaccione R, Seow CH, Targownik LE, Zelinsky S, Benchimol EI.  Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy.  Journal of the Canadian Association of Gastroenterology, 2021, 4(S2):S10-19.
 
  • Graff LA, Fowler S, Jones JL, Benchimol EI, Bitton A, Guoxian Huang J, Kuenzig ME, Kaplan GG, Lee K, Mukhtar MS, Tandon P, Targownik LE, Windsor JW, Bernstein CN.  Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 2021, 4(S2):S46-S53. 
 
  • Osei JA, Peña-Sánchez JN, Fowler SA, Muhajarine N, Kaplan GG, Lix LM. Increasing prevalence and direct health care cost of Inflammatory Bowel Disease among adults: A Population-Based study from a Western Canadian Province. Journal of the Canadian Association of Gastroenterology, 2021, 4(6):296-305.  
 
  • Osei JA, Pena-Sanchez JN, Fowler SA, Muhajarine N, Kaplan GG, Lix LM. (2021).  Population-based evidence from a western Canadian province of the decreasing incidence rates and trends of Inflammatory Bowel Disease among adults.  Journal of the Canadian Association of Gastroenterology, 2021, 4(4):186-193.
 
  • Pena-Sanchez JN, Osei JA, Marques Santos JD, Jennings D, Andkhoie M, Brass C, Bukassa-Kazadi G, Lu X, Johnson-Jennings M, Porter L, Porter R, Quintin C-L, Sanderson R, Teucher U, Fowler S.  Increasing prevalence and stable incidence rates of Inflammatory Bowel Disease among First Nations: Population-based evidence from a Western Canadian province.  Inflammatory Bowel Diseases. Epub ahead of print (25 May 2021).  

 

  • Rohatinsky N, Boyd I, Dickson A, Fowler S, Pena-Sanchez JN, Quintin CL, Risling T, Russel B, Wicks K, Wicks M.  Perspectives of health care use and access to care for individuals living with inflammatory bowel disease in rural Canada.  Rural and Remote Health, 2021, 21(2):6358. 

 

  • Marques Santos JD, Pena-Sanchez JN and Fowler SA. Patients’ Perspectives on Medication for Inflammatory Bowel Disease: A Mixed-Method Systematic Review. European Journal of Gastroenterology & Hepatology. 2021, 34(1):51-57. 

 

  • Blackburn DF, Fowler S, Crawley A, Gerwing S, Alcorn J, Mansell H, Evans C, Mansell K, Taylor J, Jorgenson D, Larocque D, Rotter T, Shewchuk Y. An Advanced Pharmacy Practice Experience for Community Pharmacies Based on a Clinical Intervention Targeting Patients with Inflammatory Bowel Disease.  Journal of Pharmacy Practice.  2021, 34(1):51-57. 

 

  • Weizman AV, Nguyen GC, Seow CH, Targownik K, Murthy SK, Boland K, Afzal NM, Khanna R, Jones J, Afif W, Halder S, Reinglas J, Fowler S, Huang V, Kaplan GG, Melmed GY. (2019). Appropriateness of Biologics in the Management of Crohn’s Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 25(2):328-335.
 
  • Duff W, Haskey N, Potter G, Alcorn J, Hunter P, Fowler S. (2018). Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance. World Journal of Gastroenterology, 24(28):3055-3070.
 
  • Haskey N, Pena-Sanchez JN, Jones JL, Fowler S. (2018). Development of a screening tool to detect nutrition risk in patients with Inflammatory Bowel Disease. Asia Pacific Journal of Clinical Nutrition, 27(4):756-762.
 
  • Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. (2018). Biomarker-based models outperform patient-reported scores in predicting endoscopic inflammatory disease activity. Inflammatory Bowel Diseases, 24(2):277-285. 
 
  • Almousa AA, Morris M, Fowler S, Jones J, Alcorn J. (2018). Elevation of serum pyruvate kinase M2 (PKM2) in IBD and its relationship to IBD indices.  Clinical Biochemistry, 53:19-24. 
 
  • Di Y, Jones J, Mansell K, Whiting S, Fowler S, Thorpe L, Bilinsky J, Viveky N, Cheng PC, Almousa A, Hadjistavropoulos T, Alcorn J. (2017). Influence of flaxseed lignan supplementation to older adults on biochemical and functional outcome measures of inflammation. Journal of the American College of Nutrition, 36(8):646-653.
 
  • Peña-Sánchez JN, Lix LM, Teare GF, Li W, Fowler SA, Jones JL. (2017). Impact of an integrated model of care on outcomes of patients with inflammatory bowel diseases: Evidence from a population-based study.  Journal of Crohn’s and Colitis, 11(12):1471-9.
 
  • Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY. (2017). Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 23:858-865.
 
  • Alcorn J, Whiting S, Viveky N, Di Y, Mansell K, Fowler S, Thorpe L, Almousa A, Cheng PC, Jones J, Billinsky J, Hadjistavropoulos. (2017). Protocol for a 24-week Randomized Controlled Study of Once-Daily Oral Dose of Flax Lignan to Healthy Older Adults. JMIR Research Protocols, 6(2):e14.
 
  • Yao S, Lix L, Li W, Shevchuk Y, Teare G, Champagne A, Fowler S, Blackburn DF. (2016). Utilization of Biologics in Saskatchewan. J Popul Ther Clin Pharmacol, 23(3):231-236.
 
  • Pedamallu CS, Bhatt AS, Bullman S, Fowler S, Freeman SS, Durand J, Jung J, Duke F, Manzo V, Cai D, Ananthakrishnan A, Ojesina A, Ramachandran A, Gevers D, Xavier RJ, Bhan AK, Meyerson M, Yajnik V. (2016). Metagenomic characterization of microbial communities In Situ within the deeper layers of the ileum in Crohn’s Disease.  Cellular and Molecular Gastroenterology and Hepatology, 2(5):563-566.
 
  • Nguyen GC, Seow CH, Maxwell C, and the IBD in Pregnancy Consensus Group (Fowler S), et al. (2016).  The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.  Gastroenterology, 150(3):734-757.
 
  • Fowler S, Jones J, Hull P, Ghosh S. (2015). Extracorporeal photopheresis for the treatment of Crohn’s disease. Transfusion and Apheresis Science, 52:183-186. 
 
  • Fowler S, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik J, Sands BE, Daly MJ, Xavier RJ, Yajnik V. (2014). SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. Journal of Crohn's and Colitis, 8(8):845-851. 
  • Juillerat P, Wasan SK, Fowler S, Friedman S, Pabby VK, Coukas JA, Barto AE, Pellish R, Germansky KA, Cheifetz AS, Korzenik J, Farraye FA, Yajnik V. (2013). Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated at 6 Boston Academic Hospitals. Inflammatory Bowel Diseases, 19(11):2457-63. 
 
  • Axelrad J, Fowler S, Friedman S, Ananthakrishnan AN, Yajnik V. (2012). Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clinical gastroenterology and hepatology, 10(9):1021-1027. 
 
  • Fowler S, Chen E, Hefny M, Ellis R, Mercer D, Jalink D, Samis A, Hookey L. (2011). A Prospective Randomized Assessment of a Spatial Orientation Device in Natural Orifice Translumenal Endoscopic Surgery (NOTES). Gastroentestinal Endoscopy, 73(1):315-324. 
 
  • Morse JWI, Fowler S, Morse AL. (2008). Endoscopist-administered Propofol: A Retrospective Safety Study. Canadian Journal of Gastroenterology, 22(7):617-620. 

 Presentations:

  • Jennings D, Peña-Sánchez JN, Johnson-Jennings M, Andkhoie M, Brass C, Bukassa-Kazadi G, Fowler S, Marques-Santos JD, Osei J, Porter L, Porter R, Quintin CL, Sanderson R, Teucher U. Inflammatory bowel disease among First Nations: a photovoice study in Saskatchewan, Canada.Indigenous Health Conference. Niagara Falls, May 2020. Note: accepted for a poster presentation although the meeting was cancelled due to the COVID-19 pandemic.

 

  • Osei JA, Pena-Sanchez J, Fowler S, Muhajarine N, Kaplan GG, Lix LM. The incidence of Inflammatory Bowel Disease is decreasing in Saskatchewan: A population-based cohort study. Canadian Digestive Diseases Week.  Montreal, Canada.  Feb 2020.  Note: poster presentation.

 

  • Peña-Sánchez JN, Jennings D, Osei J, Andkhoie M, Brass C, Bukassa-Kazadi G, Fowler S, Johnson-Jennings M, Lu X, Marques-Santos JD, Porter L, Porter R, Quintin CL, Sanderson R, Teucher U. Prevalence and incidence rates of inflammatory bowel disease among First Nations: population-based evidence from Saskatchewan, Canada.The 15th Congress of the European Crohn’s and Colitis Organization (ECCO). Vienna, Austria. February 14, 2020. Note: poster presentation.
 
  • Osei J, Pena-Sanchez JN, Fowler SA, Muhajarine N, Kaplan GG, Lix LM. Increasing prevalence and direct health care cost of inflammatory bowel disease: A population-based evidence from a western Canadian province.  The 15th Congress of the European Crohn’s and Colitis Organization (ECCO). Vienna, Austria. February 14, 2020. Note: poster presentation.
 
  • Heisler, C, Mirza R, Kits O, Zelinsky S, van Zanten S, Nguyen GC, McCurdy JD, Macmillian M, Lakatos PL, Targownik LE, Fowler SA, Rioux KP, Jones JL. Focusing on the future: reducing barriers and improving access to IBD specialty care across Canada. The 15th Congress of the European Crohn’s and Colitis Organization (ECCO). Vienna, Austria. February 14, 2020. Note: poster presentation.
 
  • Osei JA, Peña-Sánchez JN, Fowler S, Muhajarine N, Lix L. Population-based evidence on the incidence of inflammatory bowel disease in Saskatchewan from 1999-2016. The 19th Saskatchewan Epidemiology Association Symposium. Regina. October 8, 2019. Note: poster presentation.
 
  • Marques Santos JD, Brass C, Peña-Sánchez JN, Fowler S, Jennings D. Health care utilization differences between First Nations and general population with Inflammatory Bowel Disease in Saskatchewan: A patient-oriented research proposal. The 19th Saskatchewan Epidemiology Association Symposium. Regina. October 8, 2019. Note: poster presentation.
 
  • Wang S, Pena-Sanchez JN, Winquist B, Li W, Jones JL, Fowler SA. Characterization of women with Inflammatory Bowel Disease and exposure to biologics or immunomodulators during pregnancy. Gastroenterology 2019;156(6):S406. Digestive Diseases Week.  San Diego. May 2019.  Note: poster presentation. 
 
  • Hill JE, Peña-Sánchez JN, Fernando C, Freitas AC, Fowler S. The vaginal microbiome of pregnant women with inflammatory bowel disease. 4th Annual Conference Women and Their Microbes. Hamilton, Canada. March 6, 2019. Note: poster presentation.
 
  • Nero JD, Benguzzi M, Pena-Sanchez J, Fowler S. Lack of CRP response in Crohn’s disease associated with lower rates of biologic therapy: results of a single center case-control study. Journal of the Canadian Association of Gastroenterology 2019;1(Suppl 2):242-243. Canadian Digestive Diseases Week.  Banff, Canada.  March 2019.  Note: poster presentation.
 
  • Wang S, Pena-Sanchez JN, Fowler S. Pregnancy outcomes in women with Inflammatory Bowel Disease and exposure to biologics – A prospective cohort study. Journal of the Canadian Association of Gastroenterology 2018;1(Suppl 2):157-158. Canadian Digestive Diseases Week. Toronto, Canada.  Feb 2018.  Note: poster presentation.
 
  • Duff W, Haskey N, Potter GK, Hunter PV, Alcorn J, Fowler S. Non-pharmacologic therapies for Inflammatory Bowel Disease: Recommendations for self-care and physician guidance.  American Journal of Gastroenterology 2017;112(Suppl 1):S612-S613.  American College of Gastroenterology/World Congress of Gastroenterology.  Orlando, Florida.  Oct 2017.  Note: poster presentation.
 
  • Pena-Sanchez JN, Lix L, Teare GF, Li W, Fowler SA, Jones JL. A population-based study evaluating an integrated model of care for Inflammatory Bowel Disease. Gastroenterology 2017;152(5):S790. Digestive Diseases Week. Chicago, Illinois, May 2019.  Note: poster presentation. 
 
  • Pena-Sanchez JN, Lix LM Teare GF, Li W, Fowler SA, Jones JL. The impact of an integrated model of care for patients with Inflammatory Bowel Disease in Canada. Journal of Crohn’s and Colitis 2017;11(Suppl 1):S451. European Crohn’s and Colitis Organization Congress.  Barcelona, Spain.  Feb 2017.  Note: poster presentation. 
 
  • Jones J, Stewart S, Pena-Sanchez JN, Fowler S, Lix L. A population-based evaluation of Inflammatory Bowel Disease drug utilization between 1975 and 2011: lessons from the past four decades.  Canadian Digestive Diseases Week.  Montreal, Canada.  Feb 2016.  Note: poster presentation.
 
  • Morris MW, Jones J, Zello GA, Alcorn J, Pena-Sanchez JN, Fowler SA. Calculation of fecal calprotectin in healthy and IBD pregnancy.  Canadian Digestive Diseases Week.  Montreal, Canada.  Feb 2016.  Note: poster presentation.
 
  • Haskey N, Pena-Sanchez J, Jones J, Fowler S. Development and Validation of a Nutrition Screening Tool to Detect Nutrition Risk in Inflammatory Bowel Disease. Canadian Digestive Diseases Week.  Banff, Canada.  Feb 2015.  Note: poster presentation.